MLICM
BCRX icon

Metropolitan Life Insurance Company (MetLife)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,087
Closed -$51.2K – 260
2024
Q1 		$51.2K Sell
10,087
-1,545
-13% -$8.69K ﹤0.01% 1395
2023
Q4 		$69.7K Hold
11,632
– – ﹤0.01% 1271
2023
Q3 		$82.4K Buy
11,632
+1,604
+16% +$11.5K ﹤0.01% 1121
2023
Q2 		$70.6K Hold
10,028
– – ﹤0.01% 1214
2023
Q1 		$83.6K Sell
10,028
-1,438
-13% -$13.8K ﹤0.01% 1098
2022
Q4 		$132K Buy
11,466
+364
+3% +$4.54K 0.01% 917
2022
Q3 		$140K Hold
11,102
– – 0.01% 829
2022
Q2 		$117K Hold
11,102
– – 0.01% 969
2022
Q1 		$181K Sell
11,102
-36,266
-77% -$582K 0.01% 867
2021
Q4 		$656K Hold
47,368
– – 0.01% 1244
2021
Q3 		$681K Sell
47,368
-4,706
-9% -$74.2K 0.01% 1237
2021
Q2 		$823K Buy
52,074
+4,089
+9% +$55.6K 0.01% 1158
2021
Q1 		$488K Sell
47,985
-3,484
-7% -$35.9K 0.01% 1425
2020
Q4 		$383K Sell
51,469
-2,325
-4% -$12K 0.01% 1538
2020
Q3 		$185K Buy
53,794
+3,105
+6% +$13.3K ﹤0.01% 1819
2020
Q2 		$242K Sell
50,689
-1
-0% -$4 ﹤0.01% 1680
2020
Q1 		$101K Buy
50,690
+313
+0.6% +$862 ﹤0.01% 2022
2019
Q4 		$174K Buy
50,377
+13,406
+36% +$33.7K ﹤0.01% 2020
2019
Q3 		$106K Hold
36,971
– – ﹤0.01% 2273
2019
Q2 		$140K Hold
36,971
– – ﹤0.01% 2129
2019
Q1 		$301K Hold
36,971
– – 0.01% 1636
2018
Q4 		$298K Buy
36,971
+1,067
+3% +$8.3K 0.01% 1551
2018
Q3 		$274K Buy
35,904
+4,590
+15% +$30.8K ﹤0.01% 1786
2018
Q2 		$179K Hold
31,314
– – ﹤0.01% 2013
2018
Q1 		$149K Buy
31,314
+4,491
+17% +$23.1K ﹤0.01% 2078
2017
Q4 		$132K Sell
26,823
-33,253
-55% -$161K ﹤0.01% 2151
2017
Q3 		$315K Sell
60,076
-50
-0.1% -$256 ﹤0.01% 2001
2017
Q2 		$334K Hold
60,126
– – ﹤0.01% 1986
2017
Q1 		$505K Buy
60,126
+3,339
+6% +$23.2K ﹤0.01% 1648
2016
Q4 		$359K Sell
56,787
-4,399
-7% -$22.9K ﹤0.01% 1956
2016
Q3 		$270K Sell
61,186
-2,330
-4% -$9.31K ﹤0.01% 2138
2016
Q2 		$180K Buy
+63,516
New +$197K ﹤0.01% 2388
2016
Q1 		– Sell
-52,196
Closed -$539K – 2508
2015
Q4 		$539K Hold
52,196
– – ﹤0.01% 1578
2015
Q3 		$595K Hold
52,196
– – ﹤0.01% 1524
2015
Q2 		$779K Buy
+52,196
New +$593K 0.01% 1450
2015
Q1 		– Sell
-54,718
Closed -$665K – 2234
2014
Q4 		$665K Hold
54,718
– – ﹤0.01% 1568
2014
Q3 		$535K Hold
54,718
– – ﹤0.01% 1674
2014
Q2 		$698K Buy
+54,718
New +$532K ﹤0.01% 1591

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s BCRX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 10,087 shares — an estimated $51.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in BCRX in Q2 2014 and held it in 38 quarters. The position peaked at $823K in Q2 2021. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 10,087 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $51.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 38 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s BioCryst Pharmaceuticals position peaked at $823K in Q2 2021.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.